Research & Development

Research & Development

A deeply integrated, multi-disciplinary R&D approach that generates defensible IP and high-margin clinical ingredients.

R&D Advantage

Six Disciplines. One System.

Our deeply integrated R&D approach, spanning precision agronomy, bioactive pathway optimisation, and digital process control, systematically generates novel methodologies and proprietary innovations. This robust, multi-disciplinary intellectual property is highly defensible, establishing significant barriers to entry for competitors.

Precision Agronomy

Controlled light spectra, VPD, CO₂ and nutrient delivery tuned per crop and per bioactive target. Trials run in partnership with Stirling Plant Sciences.

Bioactive Pathway Optimisation

Stress-elicitation, photoperiod manipulation and fertigation adjustment to push glucosinolates, polyphenols, nitrates and other markers 3–8× above field-grown levels.

Analytical Chemistry

HPLC, mass-spectrometry and ATP-swab validation at each harvest batch, creating a closed-loop feedback system that targets specific bioactive concentration bands.

Digital Process Control

Digital-twin crop modelling with Stirling Engineering translates validated 'recipes' into predictive control algorithms that reduce energy-per-kg and improve consistency.

Renewable Energy CEA

BioLabs™ microgrid integration cuts operating costs and supports Net Zero objectives. BioCubes are engineered for low-CAPEX, off-grid-ready deployment.

Clinical Dietetics

Nutrient profiles are mapped with clinical dietetics oversight, ensuring bioactive frameworks meet medical-grade application standards for GLP-1, sports and pharmaceutical supply chains.

Our Current Focus

The Future: Peptide Research

Molecular Farming Process: Growing Peptides in a Vertical Farm
Molecular Farming

Manufacturing Peptides & Therapeutic Proteins

1 / 5
Step 1: Programming the Biological USB Drive
Proven Results

Traction to Date

2.5–4.0×
Bioactive uplift demonstrated in early potency trials
15–25 days
Proven crop cycle in pilot BioCube containers
1,000–2,500 kg
Annual yield per container across validated crops
75%
Yield gain vs hydroponics (NASA aeroponics data)
Roadmap

12–24 Month R&D Plan

Phase 1 — 0–6 Months
Foundation & Validation
  • IP filings for growing protocols
  • First BioCubes manufacture
  • Analytical assays with partnered labs
  • SEIS/EIS close
  • Initial clinical diet mapping complete
Phase 2 — 6–12 Months
Scale & Certification
  • Multi-cube R&D site at NEXUS
  • GACP & ISO 22000 certification pathway
  • First B2B supply contracts / HMPPS partnership
  • White-label sports product launch
Phase 3 — 12–24 Months
Commercial Expansion
  • 30–50 BioCubes in operation
  • International licensing (UK, EU & Caribbean)
  • Strong recurring B2B sales
  • Profitability achieved

Partners & Associates

UK Urban Agritech
EISA
East Suffolk Council
Growspec Global
NutraGenesis
Solaris
OREX
Synergy Sphere
UK Urban Agritech
EISA
East Suffolk Council
Growspec Global
NutraGenesis
Solaris
OREX
Synergy Sphere
BioLabs

The Operating System for Biologicals

EIS Round 3 Open

Navigation

Registered Office

Centrum,
Norwich Research Park
Norwich, NR4 7UG, UK
Co. Reg.: 15812659

Sales & Distribution

Units 10, 11 & 16,
Nexus Power Park
Lowestoft, NR32 1XA

In Silico Lab

Scion House,
Stirling University
Innovation Park
Stirling, FK9 4NF
"BioLabs™" is a Trading Style of Frontier Biolabs Ltd and Biolabs Corp Ltd
EISA Member · Knowledge Intensive Company

Regulatory Status

Biolabs Corp Ltd is authorised and regulated by the Financial Conduct Authority (Firm Reference Number: 1051225).

Regulatory Disclaimer

Biolabs Corp Ltd is listed on the FCA Financial Services Register under FRN 1051225. Check our registration details on register.fca.org.uk . Investment in early-stage ventures involves significant risk, including illiquidity, lack of dividends, loss of capital, and dilution.

© 2026 BioLabs. All rights reserved.